AbbVie (ABBV) Q2 FY26 earnings call

AbbVie delivered an excellent quarter, surpassing revenue and EPS expectations driven by strong performance from its diverse portfolio, particularly Skyrizi, Rinvoq, and neuroscience assets. The company is strategically bolstering its long-term growth prospects through the acquisition of Apogee Therapeutics, enhancing its immunology pipeline. Despite expected headwinds from biosimilar competition for Humira and IMBRUVICA, management remains confident in its commercial execution and pipeline advancements, raising full-year revenue guidance.